- Home
- JHI vs MNPR Comparison
JHI vs MNPR Comparison
Compare JHI & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JHI
- MNPR
- Stock Information
- Founded
- JHI 1971
- MNPR 2014
- Country
- JHI United States
- MNPR United States
- Employees
- JHI N/A
- MNPR N/A
- Industry
- JHI Trusts Except Educational Religious and Charitable
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- JHI Finance
- MNPR Health Care
- Exchange
- JHI Nasdaq
- MNPR Nasdaq
- Market Cap
- JHI 124.3M
- MNPR 113.5M
- IPO Year
- JHI N/A
- MNPR 2019
- Fundamental
- Price
- JHI $13.74
- MNPR $25.82
- Analyst Decision
- JHI
- MNPR Strong Buy
- Analyst Count
- JHI 0
- MNPR 3
- Target Price
- JHI N/A
- MNPR $27.33
- AVG Volume (30 Days)
- JHI 29.5K
- MNPR 101.2K
- Earning Date
- JHI 01-01-0001
- MNPR 11-08-2024
- Dividend Yield
- JHI 6.80%
- MNPR N/A
- EPS Growth
- JHI N/A
- MNPR N/A
- EPS
- JHI 1.05
- MNPR N/A
- Revenue
- JHI N/A
- MNPR N/A
- Revenue This Year
- JHI N/A
- MNPR N/A
- Revenue Next Year
- JHI N/A
- MNPR N/A
- P/E Ratio
- JHI $12.47
- MNPR N/A
- Revenue Growth
- JHI N/A
- MNPR N/A
- 52 Week Low
- JHI $11.63
- MNPR $1.55
- 52 Week High
- JHI $13.40
- MNPR $38.50
- Technical
- Relative Strength Index (RSI)
- JHI 26.75
- MNPR 57.88
- Support Level
- JHI $13.71
- MNPR $22.61
- Resistance Level
- JHI $14.45
- MNPR $32.20
- Average True Range (ATR)
- JHI 0.11
- MNPR 3.36
- MACD
- JHI -0.07
- MNPR -0.03
- Stochastic Oscillator
- JHI 6.31
- MNPR 47.01
About JHI John Hancock Investors Trust
John Hancock Investors Trust is a United States-based diversified, closed-end management investment company. It seeks to generate income for distribution to its shareholders. The secondary objective of the company is capital appreciation. The portfolio composition of the fund comprises corporate bonds, U.S. government agencies, preferred securities, asset-backed securities, common stocks, short-term investments, and others.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.